Premium
P2‐392: CROSS‐CULTURAL VALIDATION AND NORMATIVE STUDY OF A NEUROPSYCHOLOGICAL BATTERY USED IN THE DETERMINATION OF CLINICAL ENDPOINTS TO DELAY ONSET OF MCI
Author(s) -
WelshBohmer Kathleen A.,
Romero Heather R.,
Hayden Kathleen M.,
Plassman Brenda L.,
Atkins Alexandra Strickland,
Vaughan Adam W.,
Turcotte Nicole,
Keefe Richard S.E.,
Makeeva Oksana,
Monsch Andreas U.,
Frisoni Giovanni B.,
Melikyan Zara,
Brewster Shyama R.,
Chiang Carl,
O'Neil Janet,
Schuster Jennifer,
Lymboura Margarita,
Runyan Grant,
Atkinson Mark,
Budur Kumar
Publication year - 2014
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2014.05.1072
Subject(s) - normative , neurocognitive , psychology , neuropsychology , clinical dementia rating , construct validity , neuropsychological assessment , clinical psychology , neuropsychological test , cognition , operationalization , dementia , gerontology , developmental psychology , medicine , psychiatry , cognitive impairment , psychometrics , disease , pathology , philosophy , epistemology
smoker, active alcohol drinker, comorbid diseases, and drug number among rivastigmin (n:26), donepezil (n:15), galantamine (n:14), and control (n:23) groups (Table-1). Change in PSQI scores was different among groups (p1⁄40.002) (Table-2). Difference in change in PSQI scores was owing to fact that galantamine group showed better improvement in sleep quality than donepezil and control groups (p1⁄40.010 and p1⁄40.006, respectively) (Figure-1). After treatment, there was a significant decrease in PSQI score in Galantamine group (p1⁄40.028) (Table-2) (Figure-2). Although statistically not significant, rivastigmine decreased PSQI score and donepezil increased that post-treatment (p1⁄40.193 and p1⁄40.157, respectively) (Table-2). Rate of improvement in dementia patients with poor sleep quality (n:36) was 81.8% in galantamine group (p1⁄40.009), 75% in rivastigmine group (p1⁄40.056), and 50% in donepezil group (p1⁄40.878). Conclusions: Galantamine might be a good option for dementia patients in terms of improving sleep quality. Furthermore, galantamine and rivastigmine might decrease polypharmacy, morbidity risk, and caregiver’s burden in those with poor sleep.